Genmab A/S ADS Share Price
NASDAQ: GMABGenmab A/S ADS Stock Performance
Genmab A/S ADS Share Price Today
As of 31 October 2026, Genmab A/S ADS's share price is $57.04. The stock opened at $57.15, compared to its previous close of $56.41. During today's trading session, Genmab A/S ADS's share price traded between $56.53 and $59.00, with an average price of $57.77. Over the past 52 weeks, the stock has recorded a high of $59.95 and a low of $23.62. In terms of performance, Genmab A/S ADS's share price has risen by 115.12% over the last six months and is up 99.44% on a year-on-year basis.
Genmab A/S ADS Share Price Chart
About Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Genmab A/S ADS Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Oct 2026 | $35.25 | $56.99 | +59.67% |
Sep 2026 | $33.31 | $35.70 | +4.65% |
Aug 2026 | $28.64 | $34.11 | +18.19% |
Jul 2026 | $27.92 | $28.86 | +5.16% |
Jun 2026 | $25.78 | $27.45 | +4.18% |
May 2026 | $26.34 | $26.34 | -0.64% |
Apr 2026 | $27.25 | $26.52 | -1.23% |
Mar 2026 | $29.41 | $26.84 | -8.83% |
Feb 2026 | $32.69 | $29.45 | -9.76% |
Jan 2026 | $31.17 | $32.63 | +5.92% |
Dec 2025 | $32.38 | $30.80 | -4.82% |
Nov 2025 | $28.73 | $32.37 | +13.16% |